National Reference Centre for Group B Streptococci, Medical Microbiology Department, University Hospital of Liege, Sart Tilman B-23, 4000 Liege, Belgium.
Vaccine. 2013 Aug 28;31 Suppl 4:D31-42. doi: 10.1016/j.vaccine.2013.05.012.
Development of a group B streptococcal vaccine (GBS) vaccine is the most promising approach for the prevention of GBS infections in babies, given the potential adverse effects of intrapartum antibiotic prophylaxis as well as the need for effective prevention of both adult and late perinatal disease. There are numerous prevention strategies at this time but none are 100% effective in the eradication of neonatal early onset GBS disease and there are no preventative strategies for late onset disease. The need for a GBS vaccine is therefore, of utmost importance. Efforts applying genomics to GBS vaccine development have led to the identification of novel vaccine candidates. The publication of GBS whole genomes coupled with new technologies including multigenome screening and bioinformatics has also allowed researchers to overcome the serotype limitation of earlier vaccine preparations in the search of a universal effective vaccine against GBS. This review brings together the key arguments concerning the potential need of a GBS vaccine in developed countries and describes the current status with GBS epidemiology and microbiology in these countries.
B 群链球菌疫苗（GBS）的研发是预防婴儿 GBS 感染最有希望的方法，因为产时抗生素预防方案可能存在不良反应，并且需要有效预防成人和围产期后期疾病。目前有许多预防策略，但没有一种策略能 100%有效根除新生儿早发性 GBS 疾病，也没有针对迟发性疾病的预防策略。因此，非常有必要开发 GBS 疫苗。将基因组学应用于 GBS 疫苗开发的努力已经导致了新型疫苗候选物的鉴定。GBS 全基因组的公布，以及包括多基因组筛选和生物信息学在内的新技术，也使研究人员能够克服早期疫苗制剂在寻找针对 GBS 的通用有效疫苗方面的血清型限制。这篇综述汇集了关于发达国家开发 GBS 疫苗的潜在需求的关键论点，并描述了这些国家 GBS 流行病学和微生物学的现状。
